Is the Glow blend an approved drug or a research-use-only material?

It is supplied strictly for research use only. The Glow blend (BPC-157 + TB-500 + GHK-Cu) is not an approved drug in Canada or any other jurisdiction, is not approved for human or veterinary use, and is not intended to diagnose, treat, cure, or prevent any condition. Any parameters cited reflect what individual-component studies reported, not directions for use.

Is Glow a single peptide?

No. It is a combination product that co-formulates three separate peptides — BPC-157 (a 15-amino-acid fragment, PubChem CID 108101), TB-500/thymosin beta-4 (CID 45382195), and GHK-Cu (the copper tripeptide, CID 71587328). It has no single sequence, molecular formula, CAS number, or InChIKey; those belong to the individual components.

Has the BPC-157 + TB-500 + GHK-Cu combination itself been studied?

Not in any controlled trial. The published literature covers the three peptides individually (largely animal and in-vitro work for BPC-157 and TB-500, and small topical cosmetic trials for GHK-Cu). There are no randomized controlled trials of the blend and no published evidence of a synergistic effect from combining them in humans, so combined efficacy is Not established.

What evidence grade does the blend carry and why?

Grade C, reflecting the combination rather than the strongest single component. GHK-Cu and TB-500 each reach grade B in isolation on the strength of human topical and extensive animal data, while BPC-157 is grade C (mostly animal/in-vitro). Because no study has tested the three together, the blend as a unit is graded C, and component identities were cross-checked against PubChem while combined claims that could not be verified are described as Not established.

Glow (BPC-157 / TB-500 / GHK-Cu): Peptide Blend Research

Glow is not a single molecule but a combination product that co-formulates three separate research peptides: BPC-157 (a synthetic 15-amino-acid “body protection compound” fragment), TB-500 (the research label for thymosin beta-4 or its actin-binding fragment), and GHK-Cu (the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine). It is supplied in Canada strictly as a research-use-only material and is not an approved drug for humans or animals in any jurisdiction; it is not intended to diagnose, treat, cure, or prevent any condition. The rationale described by vendors is that each component has been studied separately in tissue-repair contexts, but the blend as a fixed combination has not itself been characterized in controlled studies, and no published human trial has evaluated these three peptides administered together.⁶

Structure

Sequence & identity

Three distinct peptides combined: BPC-157 (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) · TB-500 / thymosin beta-4 (full-length 43-mer Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES, or in some products the Ac-LKKTETQ fragment) · GHK-Cu (Gly-His-Lys · copper(II) complex). There is no single combined sequence or formula.

This is a multi-peptide blend, not one compound, so it has no unified structure, CAS number, molecular formula, or InChIKey. Component identities were cross-checked against PubChem: BPC-157 (CID 108101), thymosin beta-4 (CID 45382195), and GHK-Cu (CID 71587328).¹⁴⁵

What the research shows

Mechanisms studied

Because Glow combines three peptides, any mechanism is the sum of the separate component literatures rather than a single characterized pathway.

BPC-157. Researchers report that BPC-157 is associated with pro-angiogenic activity linked to activation and up-regulation of vascular endothelial growth factor receptor-2 (VEGFR2) and the downstream Akt-eNOS (nitric oxide) cascade in endothelial cells, and that in animal tendon and muscle models it was associated with increased fibroblast outgrowth, cell survival, and cell migration.²³

TB-500 (thymosin beta-4). Reviewers describe Tβ4 as the major actin-sequestering peptide in mammalian cells, binding monomeric G-actin in a 1:1 complex to regulate cell motility; in injury models researchers reported it promotes endothelial cell migration and angiogenesis, acts as a chemoattractant for keratinocytes, and modulates inflammation.⁴

GHK-Cu. Investigators report that GHK binds copper(II) with high affinity and delivers it into cells in a non-toxic form, and in cell and tissue models stimulates synthesis of collagen and dermal proteoglycans while modulating matrix metalloproteinases and their inhibitors (TIMP-1/TIMP-2).⁵ These mechanisms are characterized for the individual peptides in cell and animal systems; no study has demonstrated a combined or synergistic mechanism for the three together.

Reported in studies

Dosing in the research literature

The figures below summarise regimens as reported in published research — they are not recommendations or directions for use.

Source / model	Regimen reported	Notes
Component parameter — BPC-157, Krivic et al. (rat Achilles tendon-to-bone model) ³	In rat studies, BPC-157 was administered systemically (e.g. intraperitoneal/intragastric) at microgram-to-nanogram-per-kg ranges within tendon and muscle healing protocols.	This is a component animal-study parameter, NOT a directive for the blend or for any human or veterinary use. No blend-specific regimen has been published.
Component parameter — TB-500 / Tβ4, Ruff et al. Phase 1 IV PK, healthy volunteers ⁴	Single ascending intravenous doses of thymosin beta-4 (42–1260 mg per subject) were used in a Phase 1 human pharmacokinetic study; plasma half-life was reported at roughly 1–2 hours and rose with dose.	This is a single-component research administration, not a blend regimen and not usage directions. Most Tβ4 efficacy data are from topical or animal studies.
Component parameter — GHK-Cu, Pickart & Margolina (topical cosmetic trials) ⁵	GHK-Cu was formulated into topical creams and applied to facial/eye/thigh skin over roughly 12 weeks in the cosmetic trials summarized in the cited review.	This is a topical cosmetic-study parameter for one component only. It does not describe the injectable blend and is not a direction for use. No established systemic dosing exists for GHK-Cu in the published human literature.

Research use only. Peptigo products are sold to qualified researchers for laboratory use. This information summarises published research for reference and is not medical advice, a dosing recommendation, or directions for human or animal use.

Reported in studies

Effects observed in research

Reported effects are those of the individual components, not of the blend, which has not been tested as a unit. For BPC-157, animal and in-vitro studies reported associations with accelerated tendon, muscle, and other soft-tissue healing and with angiogenesis, though no adequately powered human trial has confirmed these outcomes.²³ For TB-500/thymosin beta-4, animal models reported accelerated dermal wound closure, reepithelialization, and angiogenesis, and Phase 2 human trials of topical formulations reported improvement in severe dry eye and a mid-dose signal in venous stasis ulcers; systemic “recovery” use is not validated.⁴ For GHK-Cu, small topical cosmetic trials reported improvements in skin firmness, density, and wrinkle parameters, alongside extensive in-vitro work on collagen and MMP/TIMP modulation.⁵ Crucially, no published study has measured the effects of the BPC-157 + TB-500 + GHK-Cu combination itself, and there is no evidence of synergy between the three in humans.⁶ These are study-reported observations for separate compounds in research and cosmetic settings, not claims of medical benefit for the blend.

Honest assessment

Strength of evidence

Grade C

Graded C for the blend as a whole. This grade reflects the combination, not the strongest single component. Each peptide has its own evidence base — GHK-Cu has limited human topical trials (grade B in isolation), TB-500/Tβ4 has extensive animal data plus a few Phase 2 topical trials (grade B in isolation), and BPC-157 rests almost entirely on animal and in-vitro work with only small uncontrolled human pilots (grade C in isolation).³⁴⁵ The blend specifically has essentially no direct study: there are no randomized controlled trials of these three peptides combined, and no published evidence of synergistic effect from co-administration in humans.⁶ Combining peptides also makes the contribution of any single component impossible to isolate, and fixed-ratio products vary by vendor. Component identities (formulas, masses, CAS, InChIKeys) were cross-checked against PubChem; the blend has none of its own. Where a combined or synergistic claim could not be independently verified, it is described as Not established rather than presented as fact.

Handling

Reconstitution & storage

Reconstitute with bacteriostatic water for laboratory handling. Store lyophilised material frozen and reconstituted material refrigerated. Use Peptigo’s reconstitution calculator and storage cheat sheet for working figures.

References

National Center for Biotechnology Information. PubChem Compound Summary for CID 108101, BPC-157 (H-Gly-Glu-Pro-Pro-Pro-Gly-DL-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val-OH; molecular formula C62H98N16O22; molecular weight ~1419.5 g/mol). https://pubchem.ncbi.nlm.nih.gov/compound/108101
Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. doi:10.1007/s00109-016-1488-y. PMID: 27847966. https://pubmed.ncbi.nlm.nih.gov/27847966/
Chang CH, Tsai WC, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. doi:10.1152/japplphysiol.00945.2010. https://journals.physiology.org/doi/full/10.1152/japplphysiol.00945.2010
Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-429. doi:10.1016/j.molmed.2005.07.004. PMID: 16099219 (mechanism); Ruff D, Crockford D, Girardi G, Zhang Y. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin β4 in healthy volunteers. Ann N Y Acad Sci. 2010;1194:223-229. PMID: 20536472. PubChem CID 45382195. https://pubmed.ncbi.nlm.nih.gov/16099219/
Pickart L, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108. doi:10.1155/2015/648108. PMID: 26236730. PubChem CID 71587328. https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/
No published randomized controlled trial or human study evaluates the BPC-157 + TB-500 + GHK-Cu combination as a fixed blend; the absence of combination-specific and synergy evidence is noted in independent clinical commentary on these peptides. Wellness MD Group / clinical reviews, 2025-2026 (accessed June 2026). https://wellnessmdgroup.com/blog/bpc-157-tb-500-ipamorelin-truth

Written by the Peptigo Research Team · scientifically reviewed by Peter, Peptigo Research Team · Last reviewed June 2026. We cite primary literature and flag where evidence is limited. Our sourcing & RUO policy →